Cargando…

Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study

We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylax...

Descripción completa

Detalles Bibliográficos
Autores principales: Forrest, D L, Thompson, K, Dorcas, V G, Couban, S H, Pierce, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091773/
https://www.ncbi.nlm.nih.gov/pubmed/12796794
http://dx.doi.org/10.1038/sj.bmt.1704087
_version_ 1783510059699929088
author Forrest, D L
Thompson, K
Dorcas, V G
Couban, S H
Pierce, R
author_facet Forrest, D L
Thompson, K
Dorcas, V G
Couban, S H
Pierce, R
author_sort Forrest, D L
collection PubMed
description We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Patients received a once daily subcutaneous injection of dalteparin 2500 anti-Xa i.u. commencing the day prior to starting HDCT, and continuing until day +30 post HSCT or hospital discharge, whichever came first. Dosage adjustments were made for patients developing renal failure. All bleeding episodes were recorded and graded and VOD was diagnosed and graded according to Seattle criteria. At 100 days of follow-up, the overall survival and probability of regimen-related mortality were 85 and 15%, respectively. Nine patients developed VOD. The probability of developing VOD post allogeneic and autologous HSCT was 28% (95% CI, 6–45) and 17% (95% CI, 0–32), respectively. VOD was graded as moderate (n=8) and severe (n=1). VOD resolved in all cases except for one patient who died secondary to severe VOD and multiorgan failure. Clinically significant bleeding episodes occurred in three patients; 24 patients developed minor bleeding not requiring specific therapy. All bleeding episodes resolved. These results suggest that LMWH for VOD prophylaxis is safe with a low incidence of serious bleeding events. Whether it is superior to unfractionated heparin, however, is unknown and should be addressed within the context of a randomized controlled trial.
format Online
Article
Text
id pubmed-7091773
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70917732020-03-24 Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study Forrest, D L Thompson, K Dorcas, V G Couban, S H Pierce, R Bone Marrow Transplant Article We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Patients received a once daily subcutaneous injection of dalteparin 2500 anti-Xa i.u. commencing the day prior to starting HDCT, and continuing until day +30 post HSCT or hospital discharge, whichever came first. Dosage adjustments were made for patients developing renal failure. All bleeding episodes were recorded and graded and VOD was diagnosed and graded according to Seattle criteria. At 100 days of follow-up, the overall survival and probability of regimen-related mortality were 85 and 15%, respectively. Nine patients developed VOD. The probability of developing VOD post allogeneic and autologous HSCT was 28% (95% CI, 6–45) and 17% (95% CI, 0–32), respectively. VOD was graded as moderate (n=8) and severe (n=1). VOD resolved in all cases except for one patient who died secondary to severe VOD and multiorgan failure. Clinically significant bleeding episodes occurred in three patients; 24 patients developed minor bleeding not requiring specific therapy. All bleeding episodes resolved. These results suggest that LMWH for VOD prophylaxis is safe with a low incidence of serious bleeding events. Whether it is superior to unfractionated heparin, however, is unknown and should be addressed within the context of a randomized controlled trial. Nature Publishing Group UK 2003-06-10 2003 /pmc/articles/PMC7091773/ /pubmed/12796794 http://dx.doi.org/10.1038/sj.bmt.1704087 Text en © Nature Publishing Group 2003 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Forrest, D L
Thompson, K
Dorcas, V G
Couban, S H
Pierce, R
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title_full Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title_fullStr Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title_full_unstemmed Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title_short Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study
title_sort low molecular weight heparin for the prevention of hepatic veno-occlusive disease (vod) after hematopoietic stem cell transplantation: a prospective phase ii study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091773/
https://www.ncbi.nlm.nih.gov/pubmed/12796794
http://dx.doi.org/10.1038/sj.bmt.1704087
work_keys_str_mv AT forrestdl lowmolecularweightheparinforthepreventionofhepaticvenoocclusivediseasevodafterhematopoieticstemcelltransplantationaprospectivephaseiistudy
AT thompsonk lowmolecularweightheparinforthepreventionofhepaticvenoocclusivediseasevodafterhematopoieticstemcelltransplantationaprospectivephaseiistudy
AT dorcasvg lowmolecularweightheparinforthepreventionofhepaticvenoocclusivediseasevodafterhematopoieticstemcelltransplantationaprospectivephaseiistudy
AT coubansh lowmolecularweightheparinforthepreventionofhepaticvenoocclusivediseasevodafterhematopoieticstemcelltransplantationaprospectivephaseiistudy
AT piercer lowmolecularweightheparinforthepreventionofhepaticvenoocclusivediseasevodafterhematopoieticstemcelltransplantationaprospectivephaseiistudy